Secukinumab for ankylosing spondylitis--authors' reply
Lancet
.
2014 Mar 1;383(9919):780-1.
doi: 10.1016/S0140-6736(14)60399-8.
Authors
Dominique Baeten
1
,
Wolfgang Hueber
2
Affiliations
1
Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
2
Translational Medicine-Autoimmunity, Novartis Institutes for BioMedical Research WSJ.386.10.48, Basel CH-4002, Switzerland. Electronic address: wolfgang.hueber@novartis.com.
PMID:
24581662
DOI:
10.1016/S0140-6736(14)60399-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal / administration & dosage*
Antirheumatic Agents / administration & dosage*
Female
Humans
Male
Spondylitis, Ankylosing / drug therapy*
Substances
Antibodies, Monoclonal
Antirheumatic Agents